Identification of novel cd8+ t cell epitopes in human herpesvirus 6b u11 and u90

Immunity, Inflammation and Disease

Volumn 3, Issue 2, 2015, Pages 118-131

  Halawi, Mustafa ^a   Khan, Naeem ^b   Blake, Neil ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

CD8+; Epitopes; HHV6B; T cells; Virus infected cells

Indexed keywords

EID: 84957967971     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.55     Document Type: Article

References (47)

1. Bell, L. M. 1997. Herpesvirus infections in Immunocompromised Hosts. Sem. Pediat. Infect. Dis. 8:169–177.
2. Boeckh, M., W. Leisenring, S. Riddell, R. Bowden, M. Huang, D. Myerson, T. Stevens-Ayers, M. E. D. Flowers, T. Cunningham, and L. Corey. 2003. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407–414.
3. Bollard, C.M., C. M. Rooney, and H. E. Heslop. 2012. T-cell therapy in the treatment of post-tranplant lymphoproliferative disease. Nat. Rev. Clin. Oncol. 9:510–519.
4. Cobbold, M., N. Khan, B. Pourgheysari, S. Tauro, D. McDonald, H. Osman, M. Assenmacher, L. Billingham, C. Steward, and C. Crawley, et al. 2005. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202:379– 386.
5. Heslop, H. E., K. S. Slobod, M. A. Pule, G. A. Hale, A. Rousseau, C. A. Smith, C. M. Bollard, H. Liu, M-F. Wu, and R. J. Rochester, et al. 2010. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925–935.
6. Khanna, R., S. Bell, M. Sherritt, A. Galbraith, S.R. Burrows, L. Rafter, B. Clarke, R. Slaughter, M. C. Falk, and J. Douglas, et al. 1999. Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproloferative disease. Proc Nat Acad Sci USA 96:1039–10396.
7. Leen, A. M., G. D. Myers, U. Sili, M. H. Huls, H. Weiss, K. S. Leung, G. Carrum, R. A. Krance, C-C. Chang, and J. J. Molldrem, et al. 2006. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12:1160–1166.
8. Savoldo, B., J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y-F. Lin, R. E. Quiros-Tejeira, P. Reinke, and S. Schubert, et al. 2006. Treatment of solid organ transplant recipients with autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108:2942–2949.
9. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038–1044.
10. Hislop, A. D., G. S. Taylor, D. Sauce, and A. B. Rickinson. 2007. Cellular Responses to Viral Infections in Humans: Lessons from Epstein-Barr Virus. Ann. Rev. Immunol. 25:587–617.
11. Crough, T, and R. Khanna. 2009. Immunobiology of human cytomegalovirus: from bench to beside. Clin. Micro. Rev. 22:76–98.
12. De Bolle, L., L. Naesens, and E. De Clercq. 2005. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin. Micro. Rev. 18:217–245.
13. Braun, D. K., G. Dominguez, and P. E. Pellett. 1997. Human herpesvirus 6. Clin. Micro. Rev. 10:521–567.
14. Gompels, U., J. Nicholas, G. Lawrence, M. Jones, B. Thomson, M. Martin, S. Efstathiou, M. Craxton, and H. A. Macaulay. 1995. The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution. Virology 209:29–51.
15. Dominguez, G., T.R. Dambaugh, F. R. Stamey, S. Dewhurst, N. Inoue, and P. E. Pellett. 1999. Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A. J. Virol. 73:8040–8052.
16. Okuno, T., K. Takahashi, K. Balachandra, K. Shiraki, K. Yamanishi, M. Takahashi, and K. Baba. 1989. Seroepidemi-ology of human herpesvirus 6 infection in normal children and adults. J. Clin. Micro. 27:651–653.
17. Yamanishi., K, K. Shiraki, T. Kondo, T. Okuno, M. Takahashi, Y. Asano, and T. Kurata. 1988. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 331:1065–1067.
18. De Pagter, P., R. Schuurman, E. Meijer, D. Van Baarle, E.A. Sanders, and J. J. Boelens. 2008. Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation. J. Clin. Virol. 43:361–366.
19. De Pagter, P., R. Schuurman, H. Visscher, M. De Vos, M. Bierings, A. M. van Loon, C. S. P. M. Uiterwaal, D. van Baarle, E. A. M. Sanders, and J. J. Boelens. 2008. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinicial outcome. Biol. Blood Marrow Transplant 14:831– 839.
20. Dulery, R., J. Salleron, A. Dewilde, J. Rossignol, E. M. Boyle, J. Gay, E. de Berranger, V. Coiteux, J-P. Jouet, and A. Duhamel, et al. 2012. Early Human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol. Blood Marrow Transplant 18:1080–1089.
21. Betts, B. C., J-A. H. Young, C. Ustun, Q. Cao, and D. J. Wiesdorf. 2011. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary. Biol. Blood Marrow Transplant 17:1546–1568.
22. Jaskula, E., D. Dlubek, M. Sedzimirska, D. Duda, A. Tarnowska, and A. Lange. 2010. Reactivation of cytomegalovirus, human herpesvirus 6, and Epstein–Barr virus differ with respect to risk factors and clincial outcome after heamatopoitec stem cell transplantation. Transplant. Proc. 42:3273–3276.
23. Nastke, M-D., A. Becerra, L. Yin, O. Dominguez-Amorocho, L. Gibson, L. J. Stern, and J. M. Calvo-Calle. 2012. Human CD4+ T cell response to human herpesvirus 6. J Virol. 86:4776–4792.
24. Martin, L. K., A. Schub, S. Dillinger, and A. Moosmann. 2012. Specific CD8+ T cells recognize human herpesvirus 6B. Eur. J. Immunol. 42:2901–2912.
25. Gerdemann, U., L. Keukens, J. M. Keirnan, U. L. Katari, C. T. Nguyen, A. P. de Pagter, C. A. Ramos, A. Kennedy-Nasser, S. M. Gottschalk, and H. E. Heslop, et al. 2013. Immunothera-peutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood 121:207–218.
26. Iampietro, M., G. Morissette, A. Gravel, I. Dubuc, M. Rousseau, A. Hasan, and R. J. O’Reilly, et al. 2014. Human herpesvirus 6B immediate-early I protein contains functional HLA-A* 02, HLA-A* 03, and HLA-B* 07 class I restricted CD8+ T-cell epitopes. Eur. J. Immunol. 44:3573–3584.
27. Sylwester, A. W., B. L. Mitchell, J. B. Edgar, C. Taormina, C. Pelte, F. Ruchti, P. R. Sleath, K. H. Grabstein, N. A. Hosken, and F. Kern, et al. 2005. Broadly targeted humancytomega-lovirus-specific CD4+ and CD8+ T cells dominate the menory compartments of exposed subjects. J. Exp. Med. 202:673–685.
28. Tejada-Simon, M. V., Y. C. Zang, J. Hong, V. M. Rivera, J. M. Killian, and J. Z. Zhang. 2002. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilo-dalton virion protein in patients with multiple sclerosis and in controls. J. Virol. 76:6147–6154.
29. Yasukawa, M., Y. Yakushijin, M. Furukawa, and S. Fujita. 1993. Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus. J. Virol. 67:6259–6264.
30. Yakushijin, Y., M. Yasukawa, and Y. Kobayashi. 1991. T-cell immune response to human herpesvirus-6 in healthy adults. Micro. Immunol. 35:655–660.
31. Khan, N., A. Hislop, N. Gudgeon, M. Cobbold, R. Khanna, L. Nayak, A. B. Rickinson, and P. A. H. Moss. 2004. Herpesvirus-specific CD8 T cell immunity in old age: Cytomegalovirus impairs the response to coresident EBV infection. J. Immunol. 173:7481–7489.
32. Yakushijin, Y., M. Yasukawa, and Y. Kobayashi. 1992. Establishment and functional characterization of human herpesvirus 6-specific CD4+ human T-cell clones. J. Virol. 66:2773–2779.
33. Ressing, M. E., D. Horst, B. D. Griffin, J. Tellam, J. Zuo, R. Khanna, M. Rowe, and E. J. Wiertz. 2008. Epstein–Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products. Sem. Can. Biol. 18:397–408.
34. Noriega, V., V. Redmann, T Gardner, and D. Tortorella. 2012. Diverse immune evasion strategies by human cytomegalovirus. Immunol. Res. 54:140–151.
35. Glosson, N. L, and A. W. Hudson. 2007. Human herpesvirus-6A and-6B encode viral immunoevasins that downregulate class I MHC molecules. Virology 365:125–135.
36. Dagna, L., J. C. Pritchett, and P. Lusso. 2013. Immunodmo-dulation and immunosuppression by human herpesvirus 6A and 6B. Future Virol. 8:273–287.
37. Takahashi, K., S. Sonoda, K. Higashi, T. Kondo, H. Takahashi, M. Takahashi, and K. Yamanishi. 1989. Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus. J. Virol. 63:3161–3163.
38. Wang, F., J. Chi, G. Peng, F. Zhou, J. Wang, L. Li, D. Feng, F. Xie, B. Gu, and J. Qin, et al. 2014. Development of virus-specific CD4+ and CD8+ regulatory T cells induced by human herpesvirus 6 infection. J. Virol. 88:1011–1024.
39. de Pagter, A. P. J., J. J. Boelens, J. Scherrenburg, T. Vroom-de Blank, K. Tesselaar, N. Nanlohy, E. A. M. Sanders, R. Schuurman, and D. van Baarle. 2012. First analysis of human herpesvirus 6 T-cell responses: Specifci boosting after HHV6 reactivation in stem cell transplantation recipients. Clin. Immunol. 144:179–189.
40. Papadopoulou, A., U. Gerdemann, U. Katari, I. Tzannou, H. Liu, C. Martinez, K. Leung, G. Carrum, A. P. Gee, and J. F. Vera, et al. 2014. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BK, and HHV6 infections after HSCT. Sci Transl Med 6:242ra83.
41. Rammensee, H-G., J. Bachmann, N. N. Emmerich, O. A. Bachor, and S. Stevanocvic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219.
42. Schmidt, A. H., D. Baier, U. V. Solloch, A. Stahr, N. Cereb, R. Wassmuth, G. Ehninger, and C. Rutt. 2009. Estimation of high-resolution HLA-A,-B,-C,-DRB1 allele and haplotype frequencies based on 8862 German stem cell donors and implications for strategic donor registry planning. Hum. Immunol. 70:895–902.
43. Rist, M., C. Smith, M. J. Bell, S. R. Burrows, and R. Khanna. 2009. Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self/non-self recognition. Blood 114:224–2253.
44. Steven, N. M., N. E. Annels, A. Kumar, A. M. Leese, M. G. Kurilla, and A. B. Rickinson. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein–Barr virus-induced cytotoxic T cell response. J Exp Med 185:1605–1617.
45. Marsh, S. G. E., P. Parham, and L. D. Barber, 2000. The HLA facts book. London, Uk: Academic Press 2000.
46. Mayne, M., C. Cheadle, S. S. Soldan, C. Cermelli, Y. Yamano, N. Akhyani, and J. E. Nagel, et al. 2001. Gene expression profile of herpesvirus-infected T cells obtained using immunomicroarrays: induction of proinflammatory mechanisms. J. Virol. 75:11641–11650.
47. Kern, F., N. Faulhaber, C. Fröommel, E. Khatamzas, S. Pröosch, C. Schöonemann, I. Kretzschmar, R. Volkmer-Engert, H. D. Volk, and P. Reinke. 2000. Analysis of CD8 T cell reactivity to cytomegalovirus using proteinöospanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 30:1676–1682.